Stock analysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a report released on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Akari Therapeutics Trading Down 13.6 % NASDAQ:AKTX opened at $2.60 on Friday. The company’s 50 day moving average price is $3.01 and […]